Entrada Therapeutics (TRDA) Current Deferred Revenue (2023 - 2026)
Entrada Therapeutics (TRDA) reported Current Deferred Revenue of $173,000 for Q2 2026, down 74.9% from $689,000 a year earlier and down 31.9% from the prior quarter.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Current Deferred Revenue (2023 - 2026) Analysis & Trends
At the end of FY2025, Entrada Therapeutics posted Current Deferred Revenue of $342,000, down 97.5% from FY2024.
- By year, Current Deferred Revenue came in at $13.65 million in FY2024 (-89.7%) and $132.26 million in FY2023.
- The Q2 2026 figure ranks as the lowest quarterly Current Deferred Revenue in data going back to Q1 2023.
- Year over year, Current Deferred Revenue has now declined in each of the last nine quarters, with an average decline of 88.7% over the last eight quarters.
- The high point for year-over-year Current Deferred Revenue in five years was Q1 2024 (growth of 21.4%); the low point was Q3 2025 (a decline of 99.2%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $254,000 (Q1 2026), $342,000 (Q4 2025) and $351,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Entrada Therapeutics | 205.54 Mn | -172.82 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 98,000.00 |
| Jun 30, 2026 | 173,000.00 |
| Mar 31, 2026 | 254,000.00 |
| Dec 31, 2025 | 342,000.00 |
| Sep 30, 2025 | 351,000.00 |
| Jun 30, 2025 | 689,000.00 |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 13.65 Mn |
| Sep 30, 2024 | 45.92 Mn |
| Jun 30, 2024 | 60.50 Mn |
| Mar 31, 2024 | 148.46 Mn |
| Dec 31, 2023 | 132.26 Mn |
| Sep 30, 2023 | 148.44 Mn |
| Jun 30, 2023 | 101.65 Mn |
| Mar 31, 2023 | 122.34 Mn |
API Access
Entrada Therapeutics Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=TRDA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "TRDA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=TRDA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();